Zobrazeno 1 - 9
of 9
pro vyhledávání: '"N. S. Maksimchuk-Kolobova"'
Publikováno v:
Фармакоэкономика, Vol 13, Iss 2, Pp 124-131 (2020)
Aim. To evaluate clinical-economical effectiveness of direct oral anticoagulants (DOAC) dabigatran, rivaroxaban, and apixaban in comparison with warfarin in atrial fibrillation (AF) therapy.Materials and Methods. Mathematical modeling (tree derivatio
Externí odkaz:
https://doaj.org/article/cc6fc2bceb414e869ac4c0905a209cec
Publikováno v:
Фармакоэкономика, Vol 12, Iss 3, Pp 191-199 (2019)
Objective: to analyze whether comorbidity affects the cost of treatment and medical services in elderly patients with atrial fibrillation (AF). Materials and methods. We conducted a retrospective analysis of 98 patients with AF. Comorbidity was evalu
Externí odkaz:
https://doaj.org/article/e3ca3d355eeb42738a1f06b84c3acd01
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 9, Iss 3, Pp 251-257 (2015)
Aim. To evaluate the economic effectiveness of the combined two-drug antihypertensive therapy in patients with arterial hypertension (HT) and high cardiovascular risk by Markov’s modeling.Material and methods. Patients (n= 65; 19 males and 46 femal
Externí odkaz:
https://doaj.org/article/5e0260ff4bbf4d28be17f1a57799203c
Publikováno v:
South Russian Journal of Therapeutic Practice. 3:60-67
Objective: to study the interconditionality of changes in the fluid shear stress on the endothelium (FSE) of the common carotid artery (CCA) wall which is intact from atherosclerosis with the value of the Cardiac Calcium Score (CCS) among patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::223168f369d45814fef1d2b2a5b321b1
https://doi.org/10.21886/2712-8156-2022-3-3-60-67
https://doi.org/10.21886/2712-8156-2022-3-3-60-67
Publikováno v:
Фармакоэкономика, Vol 13, Iss 2, Pp 124-131 (2020)
Aim. To evaluate clinical-economical effectiveness of direct oral anticoagulants (DOAC) dabigatran, rivaroxaban, and apixaban in comparison with warfarin in atrial fibrillation (AF) therapy. Materials and Methods. Mathematical modeling (tree derivati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77c9c5bc34331e6b55a369c69a566d36
https://www.pharmacoeconomics.ru/jour/article/view/385
https://www.pharmacoeconomics.ru/jour/article/view/385
Publikováno v:
Cardiovascular Therapy and Prevention. 22:3376
Aim. To study cardiovascular risk factors, clinical manifestations and management of myocardial infarction (MI) in elderly and longliving patients depending on geriatric status.Material and methods. Out of 92 patients with MI (mean age, 81,6±4,2),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81c5efd512dfb01a8939b58725af024d
https://doi.org/10.15829/1728-8800-2023-3376
https://doi.org/10.15829/1728-8800-2023-3376
Publikováno v:
European Heart Journal. 42
Introduction The average age of patients with acute coronary syndrome ACS has been progressively increasing in recent decades. Recommendations for the management of patients with ACS emphasize the importance of a patient-oriented approach, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c457e06d3c29e2a2bee79fa54523e11d
https://doi.org/10.1093/eurheartj/ehab724.2825
https://doi.org/10.1093/eurheartj/ehab724.2825
Publikováno v:
Фармакоэкономика, Vol 12, Iss 3, Pp 191-199 (2019)
Objective: to analyze whether comorbidity affects the cost of treatment and medical services in elderly patients with atrial fibrillation (AF). Materials and methods. We conducted a retrospective analysis of 98 patients with AF. Comorbidity was evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbbbbcf1eb6cb40d0255c5f0b6061972
https://www.pharmacoeconomics.ru/jour/article/view/300
https://www.pharmacoeconomics.ru/jour/article/view/300
Publikováno v:
European Heart Journal. 41
Purpose To evaluate the clinical and economic effectiveness of direct oral anticoagulants (DOAC) - dabigatran/D, rivaroxaban/R, apixaban/A compared with warfarin/W in the treatment of atrial fibrillation (AF). Methods The mathematical model (MM) was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62f39836dae66068008026c3d927db0f
https://doi.org/10.1093/ehjci/ehaa946.3374
https://doi.org/10.1093/ehjci/ehaa946.3374